Teva may have just dodged a lengthy delay in closing its $40 billion-plus deal for Allergan's generics business.
Teva is aiming to widen its lead as the world's largest generic drugmaker by folding in Allergan's knockoffs portfolio. But first, it has to get by antitrust regulators--something it's aiming to accomplish this week in the EU.
IBM has been on a tear in healthcare since it formed its Watson Health business last April. Now, in its fourth major health data deal it's slated to acquire Ann Arbor, MI-based Truven Health Analytics. The acquisition is expected to help flesh out Watson Health's core focus on cloud-based healthcare data and analytics.
Stryker is on an acquisition spree. The company announced the $1.28 billion acquisition of Physio-Control International from Bain Capital Private Equity, the company's third M&A; deal of the year, and second to cross the $1 billion mark.
Shire, awaiting the close of its $32 billion merger with Baxalta, is planning to move away from its penchant for acquisitions and focus on developing and launching products, CEO Flemming Ornskov said.
Shire's been somewhat of an M&A; machine as of late, making a string of deals that most recently included its largest-ever, Baxalta. But it's an old standby that helped the company beat analyst estimates for Q4.
Beijing, China-based contract research organization Pharmaron has snapped up fellow CRO Quotient Bioresearch as it looks to broaden its reach both technically and geographically.
Mylan Chairman Robert Coury knows rejection but also the value of persistence. Four months after being spurned by Perrigo shareholders, he has a $7.2 billion deal to buy Sweden's Meda, a company that two years ago rejected an earlier Mylan proposal.
Pfizer's planned $160 billion merger with Allergan has some researchers worried the company will embrace its counterpart's austere approach to R&D; and mount major layoffs.
After months of agitating and activism from miffed shareholders, Astellas has finally convinced the majority of Ocata Therapeutics investors to accept its $8.50-a-share offer, ending a surprisingly protracted process for the Japanese drugmaker.